Leader, Myeloproliferative Disorders Program; Professor, Member and Attending Physician, Memorial Sloan Kettering Cancer Center
Hematology
Dr. Michael J. Mauro, MD
|
|
Give Review
Michael J. Mauro, MD practices Hematology. He went to medical school at Geisel School of Medicine at Dartmouth. Geisel School of Medicine at Dartmouth is ranked 37 in research and 29 in primary care medicine He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Michael Mauro is also published. He has 43 publications published. The lastest publication: "Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.'
Publications
- Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
- Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.
- Prognostic significance of early molecular response in chronic myeloid Leukemia patients treated with tyrosine kinase inhibitors.
- Integrating Current Treatment Options for TKI-Resistant Chronic Myeloid Leukemia: General Discussion.
- Extending the reach of nilotinib in chronic myeloid Leukemia.
- The challenge of the 'C' in CML.
- Pityriasis Rubra pilaris-like eruption associated with the multikinase inhibitor ponatinib.
- Sequential therapy in chronic myelogenous Leukemia: general discussion.
- Striving to achieve safe, permanent treatment discontinuation in chronic myeloid Leukemia.
- Ponatinib in patients with refractory Acute myeloid leukaemia: findings from a phase 1 study.
- Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies.
- Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous Leukemia.
- Will Imatinib Compromise Reproductive Capacity?
- Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated Leukemias.
- Intolerance to tyrosine kinase inhibitors in chronic myeloid Leukemia: Definitions and clinical implications.
- Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) Acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.
- Drug plasma monitoring in CML and GIST: A case-based discussion.
- Review: Imatinib plasma trough levels in the management of CML: Ready for prime time?
- Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid Leukemia on imatinib.
- Response dynamics in chronic-phase chronic myeloid Leukemia.
- Tailoring tyrosine kinase inhibitor therapy in chronic myeloid Leukemia.
- Appropriate sequencing of tyrosine kinase inhibitors in chronic myelogenous Leukemia: when to change? A perspective in 2009.
- An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid Leukemia patients undergoing kinase inhibitor therapy.
- A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid Leukemia with an imatinib-induced complete cytogenetic response.
- Mutational analysis and overcoming imatinib resistance in chronic myeloid Leukemia with novel tyrosine kinase inhibitors.
- BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.
- Stem cell transplantation in patients with chronic myelogenous Leukemia: when should it be used?
- Defining and managing imatinib resistance.
- Chronic myeloid Leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment.
- Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of Chronic phase CML patients treated with imatinib mesylate.
- Images in clinical medicine. Hyperleukocytosis in Acute myeloid leukemia.
- STI571 as a targeted therapy for CML.
- The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.
- Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous Leukemia patients: 14 months' experience.
- STI571: a paradigm of new agents for cancer therapeutics.
- Recent advancements in the treatment of chronic myelogenous Leukemia.
- Overcoming Resistance in Chronic Myelogenous Leukemia.
- Management of drug toxicities in Chronic myeloid leukaemia.
- Chronic myeloid Leukemia in 2006: a perspective.
- Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission.
- Baseline disease risk and response to therapy in chronic myeloid Leukemia: necessary predictive tools then and now.
- Transplantation for chronic myelogenous Leukemia: yes, no, maybe so. . . An Oregon perspective.
Schools
Dartmouth Medical School
Ny Hospital Cornell University Mc
Cornell University Med College
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Central Nervous System Lymphoma
- Chronic Myeloid Leukemia (CML)
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
New York Presbyterian Hospital -
New York Presbyterian Hospital - Cornell Campus -
Geisel School of Medicine at Dartmouth
Hospital
-
Memorial Sloan-Kettering Cancer Center
Drug Facts
| NPI NUMBER | 1609884188 | |
| NPPES Provider LastName | MAURO | |
| NPPES Provider FirstName | MICHAEL | |
| NPPES Provider ZIPCode | 972393011 | |
| NPPES Provider State | OR | |
| Specialty Description | Hematology | |
| Total Claim Count | 273.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1609884188 |
| Last Name Of The Provider | MAURO |
| First Name Of The Provider | MICHAEL |
| View All |
Similar Doctors
|
|
Dr. Phoebe E. Harvey, MD |
|
|
Dr. Matthew C. Frank, MD |
|
Dr. Rebecca L. Orwoll, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gina Vaccaro, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert J. Raish, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ann W. Gramza, MD |
|
|
Dr. William R. Skach, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. David C. Calverley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kyle W. Robinson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Galit Perets Avraham, MD |